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It has been shown that cyclic GMP (cGMP)modulates the inflammatory responses of macrophages, but the underlyingmolecular mechanisms are
still poorly understood. Looking for proteins potentially regulated by cGMP in rat peritoneal macrophages (PMs), in this study we analyzed
expression and activity of cGMP-hydrolyzing and cGMP-regulated phosphodiesterases (PDEs). It was found that freshly isolated peritoneal exudate
macrophages (PEMs) express enzymes belonging to families PDE1-3, PDE5, PDE10, and PDE11. Analysis of substrate specificity, sensitivity to
inhibitors, and subcellular localization showed that PDE2 and PDE3 are the main cGMP-regulated PDE isoforms in PEMs. The profile of PDE
expression was altered by maintaining PEMs in culture and treatment with bacterial endotoxin (LPS). After 24 h culture, PDE5 was not present and
the levels of PDE2, PDE3, and PDE11 were markedly decreased. However, their expression and activity was recovered after treatment of cultured
cells with LPS. A similar pattern of changes was observed for the expression of TNFα, but not for guanylyl cyclase A (GC-A). LPS up-regulated PDE
expression also in resident peritoneal macrophages (RPMs), although not all PDEs present in PEMs were detected in RPMs. Taken together, our
results show that in rat PMs expression of cGMP-dependent PDEs positively correlates with the activation state of cells. Moreover, the fact that most
of these PDEs hydrolyze also cAMP indicates that cGMP can play a role of potent regulator of cAMP signaling in macrophages.
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Macrophages are key participants in both innate and adaptive
immunity. They phagocytize invading microorganisms as well
as apoptotic and necrotic cells of the host, secrete mediators of
inflammation, and present antigens to T cells [1]. The activation
of macrophages occurs in response to various signals ofAbbreviations: EHNA, erythro-9-(2-hydroxy-3-nonyl)adenine; GC, guany-
lyl cyclase; HBSS, Hank's balanced salt solution; IBMX, 3-isobutyl-1-
methylxanthine; PDE, phosphodiesterase; PEM, peritoneal exudate macro-
phage; PMSF, phenylmethylsulfonyl fluoride; RPM, resident peritoneal
macrophage; RT-PCR, reverse transcription polymerase chain reaction
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activators of the macrophage response is bacterial endotoxin
(lipopolysaccharide, LPS), which by binding to CD14 and Toll-
like receptors activates intracellular signaling pathways leading
to synthesis of nitric oxide (NO) and the inflammatory
cytokines, TNFα, IL-6, Il-1β [3–7]. Uncontrolled release of
these mediators can be dangerous for the host organism.
Therefore, the proinflammatory response of macrophages is
suppressed in several ways, including those initiated by increase
in intracellular cAMP. Compounds elevating intracellular cAMP
have been shown to decrease secretion of TNFα, IL-6, IL-1β, or
nitric oxide by activated macrophages [8–14]. Increased cAMP
may result not only from the activation of its synthesis, but also
from inhibition of its degradation by phosphodiesterases
(PDEs). In this context, the role of cAMP-specific PDEs in
monocytes and macrophages appears to be significant and has
been investigated by several laboratories [4,5,14–20]. Among
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PDE6, and PDE9) are exclusively cGMP-specific, five (PDE1,
PDE2, PDE3, PDE10, and PDE11) hydrolyze both cAMP and
cGMP, and three (PDE4, PDE7, and PDE8) are cAMP-specific
[21]. Of all PDEs, enzymes belonging to the PDE4 family have
been the most studied due to their established role in the
regulation of inflammatory responses in various cells including
monocytes and macrophages [4,5,16,17,19,22–24].
At the same time, much of the published data has indicated
that cGMP can modulate essential functions of macrophages
such as chemotaxis [25], phagocytosis [26], cytotoxicity [27],
and synthesis of inflammatory mediators [28–30]. Despite a
growing body of evidence for the roles of cGMP, little is known
about mechanisms of its action in macrophages. Generally,
intracellular signaling by cGMP is initiated with synthesis by
guanylyl cyclases (GCs), is exerted through activation of
effector proteins including cGMP-dependent protein kinases
(PKGs), cGMP-regulated PDEs, and cyclic nucleotide-gated
channels and is terminated with its degradation by PDEs [31].
However, available data on the expression and activity of
proteins involved in cGMP signaling in macrophages are
incomplete and scattered among many research models includ-
ing macrophage-like cell lines, monocytes differentiated in vitro
tomacrophages, and alveolar or peritoneal macrophages isolated
from various species.
Peritoneal exudate macrophages (PEMs) are similar to LPS-
treated mononuclear phagocytes in that they are highly
activated and synthesize large amounts of inflammatory
mediators such as cytokines TNFα and IL-6 [3,6,32]. Our
previous studies showed that in rat PEMs the particulate GC
type A (GC-A) is the only enzyme which actively synthesizes
cGMP and that these cells do not contain PKG [33]. At the same
time our studies found high PDE activity against cGMP, which
could be stimulated by cGMP itself [34]. Furthermore,
an elevation of intracellular cGMP did not cause an increase
in Ca2+ suggesting that the cGMP-gated channels were also
absent (unpublished observation). Therefore, it was justified to
suspect that the cGMP-regulated PDEs could be the main
effectors of cGMP in PEMs.
In this study we establish which isoforms of PDEs
hydrolyzing cGMP and/or regulated by cGMP are present in
rat peritoneal macrophages. Using resident peritoneal macro-
phages (RPMs) and peritoneal exudate macrophages untreated
or treated with LPS, we have also attempted to determine
whether the expression and activity of these PDEs may depend
on the activation state of the cells. We show that rat peritoneal
macrophages express several cGMP-regulated and cGMP-
hydrolyzing PDEs and that their expression correlates with the
activation state of cells.
2. Materials and methods
2.1. Materials
[3H]cAMP and [3H]cGMP were from New England Nuclear Life Science
Products (Otwock, Poland). AG1-X2 resin was purchased from BioRad
Laboratories (Hercules, CA, USA.). NucleoTrap Mini Kit was from Machery-
Nagel (Düren, Germany). Trizol® Reagent and thioglycollate were fromGibcoBRL (Paisley, Great Britain). RevertAid™ First Strand cDNA Synthesis
Kit was purchased fromMBI Fermentas (Vilnius, Lithuania). PCR Core Kit was
from Qiagen (Hilden, Germany). Sildenafil was a gift kindly provided by Pfizer
(New York, NY, USA). Agarose MEEO was from Roth (Karlsruhe, Germany).
ANP, milrinone, and forskolin were from Calbiochem-Novabiochem (Darm-
stadt, Germany). IBMX, cAMP, cGMP, Crotulus atrox snake venom, EHNA,
rolipram, and zaprinast were from Sigma-Aldrich Co (St. Louis, MO, USA).
2.2. Isolation of peritoneal macrophages and cell culture
Wistar male rats (250–300 g) were obtained from the colony at the Institute
of Immunology and Experimental Therapy in Wrocław. The animals were fed a
standard diet and water ad libitum, and the experiments were conducted in
accordance with procedures approved by the local Ethics Committee for Animal
Experimentation in Wrocław. To obtain resident peritoneal macrophages
(RPMs), untreated rats were sacrificed and after laparotomy, the peritoneal
cavity lavages with 20 ml of sterile Hank's balanced salt solution (HBSS) were
collected [35]. To obtain peritoneal exudate macrophages (PEMs), the rats were
intraperitoneally injected with 10 ml of thioglycollate. Four days later the
animals were sacrificed and peritoneal exudate cells were harvested [34]. After
two washes with HBSS, the cells were resuspended in RPMI 1640
supplemented with 10% fetal bovine serum, 0.03% L-glutamine, 100 U/ml
penicillin, 0.25 μg/ml amphotericin, 0.1 mg/ml streptomycin and plated in tissue
culture dishes at 1×106 cells/ml for 45 min at 37 °C in 5% CO2 atmosphere.
Non-adherent cells were removed and adherent macrophage monolayers where
then cultured in RPMI 1640 supplemented as indicated above. Immediately after
isolation, RPMs were cultured for 3 h with or without 1 μg/ml LPS, whereas
PEMs were cultured either for 30 min or 24 h and then used in experiments. In
some assays 24 h cultured PEMs were incubated for further 3 or 24 h in the
presence of 1 μg/ml LPS. Purity of macrophages was monitored by
morphological evaluation and by staining for nonspecific esterase. Cell viability
was determined by trypan blue exclusion. By these criteria, more than 95% of
adherent cells were viable macrophages.
2.3. Induction and measurement of intracellular cyclic nucleotides
Isolated macrophages were transferred into a 48-well microplate and allowed
to rest for 30 min at 37 °C before experiments were performed. Each well
contained 2.5×105 cells in a final volume of 0.5 ml. Cells were then
supplemented with PDE inhibitors (IBMX, milrinone or dipirydamole) and
with activators of guanylyl cyclase (ANP) and adenylyl cyclase (forskolin). All
samples were prepared in quadruplicate. After a 30 min incubation, the reaction
was terminated, cells were lysed, and intracellular cGMP was determined as
described in detail previously [33]. Briefly, accumulated cyclic nucleotides
(cGMP or cAMP) were measured using immunoenzymatic assay based on rabbit
polyclonal antibodies highly specific either for cGMP or for cAMP. To improve
sensitivity, the samples and standard solutions of cyclic nucleotides were
acetylated before the assay. After incubation with primary antibodies, the
samples were washed and incubated for 1 h at room temperature with anti-rabbit
IgG goat antibodies conjugated to horseradish peroxidase. The color reactionwas
developed using tetramethylbenzidine as a substrate and the absorbance was
measured in a Dynatech MR5000 plate reader. The amount of a given cyclic
nucleotide in the sample was calculated from a calibration curve prepared for
each plate separately.
2.4. RNA isolation and RT-PCR
Total RNAwas extracted from 5×107 peritoneal macrophages with TRIzol
reagent following the manufacturer's protocol. The yield of extracted RNAwas
determined spectrophotometrically and its quality was checked in 1.5% agarose
gels by staining with ethidium bromide. The mRNA was isolated employing
NucleoTrap mRNA Mini Kit and 0.5 μg of obtained mRNA was reverse
transcribed (RT) into cDNA using RevertAid™ First Strand cDNA Synthesis
with oligo(dT)18 primers, according to the supplier's instructions. Specific
primers used for amplification of the desired cDNAwere chosen with sequences
unique to each protein and confirmed by BLAST search. Primer sequences, their
accession numbers, annealing temperatures (TA), and expected sizes of PCR
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polymerase using cDNA and 0.4 μM of each sense and antisense primers for 35
cycles of denaturation (0.5 min, 94 °C), annealing (1 min, temperatures as
indicated in Table 1), and extension (1 min, 72 °C) with a 5-min extension at
72 °C after the last cycle. The PCR products were separated in 1.5% agarose,
visualized under UV light using ethidium bromide and the resulting images were
captured and analyzed using Fragment Analysis software (Molecular Dynamics/
Amersham Pharmacia Biotech, Sunnyvale, CA, USA). No products were
observed in control (RT−) samples, in which the reverse transcriptase was
omitted.
2.5. Preparation of subcellular fractions and PDE assay
The procedures were performed at 4 °C according to Germain et al. [36].
Macrophage monolayers were washed once in cold PBS, then scraped using
rubber policemen into a homogenization buffer (10 mM Tris–HCl, pH 7.5,
containing 1 mM MgCl2, 1 mM DTT, 5 μM pepstatin A, 10 μM leupeptin,
50 μM PMSF, 10 μM soybean trypsin inhibitor and 1 mM benzamidine) and
sonicated on ice. The homogenate was centrifuged at 100,000×g for 1 h. The
supernatant was collected and the pellet resuspended in an equal volume ofTable 1
Primers used in PCR
Gene Primer sequence
HPRT Forward 5′-AGT GAT GAT GAA CCA GGT TA-3′
Reverse 5′-ATT ATA GTC AAG GGC ATA TC-3′
PDE1A Forward 5′-TGG AAG CTG CAC TAC AGG TG-3′
Reverse 5′-CTT CAG GTC CAC AGC TGA CA-3′
PDE1B Forward 5′-TGC CCT TCT CTC CAC TCT GT-3′
Reverse 5′-TGG TTG TGC TCATCT TCT GC-3′
PDE1C Forward 5′-GCA GCA GAATGG TGA CTT GA-3′
Reverse 5′-GGG ATC TCA GGC AAATTT CA-3′
PDE2A Forward 5′-GAG GAC ATC GAG ATC TTT GC-3′
Reverse 5′-TCT TTG TAG ATC AGC TCC GC-3′
PDE3A Forward 5′-TCT TTG CCA CTC CTA CGA CT-3′
Reverse 5′-CTG TGC CTG ATA AAC ACT GC-3′
PDE3B Forward 5′-GGT AGT TCT CAC TCC TAA GC-3′
Reverse 5′-ATG GAA CAG TGT ACT GCC AC-3′
PDE4A Forward 5′-GCG GGA CCT AGC TGA AGA AAT TCC-3′
Reverse 5′-CAG GGT GAG TCC ACATCG TGG-3′
PDE4B Forward 5′-CAG CTC ATG ACC CAG ATA AGT GG-3′
Reverse 5′-GTC TGC ACA AGT GTA CCATGT TGC G-3′
PDE4C Forward 5′-ACT GAG TCT GCG CAG GAT GG-3′
Reverse 5′-CAC TCC TCT TCC TCT GCT CTC CTC-3′
PDE4D Forward 5′-CCC TCT TGA CTG TTA TCATGC ACA CC-3
Reverse 5′-GAT CCT ACA TCATGT ATT GCA CTG GC-3′
PDE5A Forward 5′-CTG TCT GAT CTG GAA ACA GC-3′
Reverse 5′-GCA ATC AGC AAT GCA AGC GT-3′
PDE9A Forward 5′-ATG GAC CGA GAC AAA GTG AC-3′
Reverse 5′-AGG CGA ACG GTC TTC ATT GT-3′
PDE10A Forward 5′-CTG AGG GGG ATG AGATGA AG-3′
Reverse 5′-TCA GTT GCT AGG CAG ACATCA-3′
PDE11A Forward 5′-TTC AGC TCG GAC AGT CCT AAA-3′
Reverse 5′-TCC ACT AGC AAA GGA GAC GAA-3′
GC-A Forward 5′-AGC AGC AAC ATC CTG GAC AA-3′
Reverse 5′-CAA AGT TGT CTA TGA CAG CA-3′
sGCα Forward 5′-CTT CAA GGG TTA TGG ACC TC-3′
Reverse 5′-TCT GAG AAG AGC ATG GTG AC-3′
sGCβ Forward 5′-CTC AAC GAC CTC TAC ACC AG-3′
Reverse 5′-CCT CTG TGC TCC AAG TGG AA-3′
PKG I Forward 5′-ACC GAG GTT ATG CCA AAC TG-3′
Reverse 5′-TCC CAG TTA AAG CCC TCA AA-3′
PKG II Forward 5′-GGA CTG CCT CTG TGA AAG CT-3′
Reverse 5′-ACT CTT CCG AAC CCA CCA AC-3′
TNF-α Forward 5′-ACT GAA CTT CGG GGT GAT TA-3′
Reverse 5′-GTG GGT GAG GAG CAC GTA GT-3′homogenization buffer. The supernatants and resuspended pellets were then
used as a soluble and particulate fractions, respectively. The PDE activity was
determined in the obtained fractions at 37 °C according to the procedure
described previously [34]. Briefly, the reaction samples (100 μl final volume)
were prepared in duplicate and contained 40 mMHEPES, pH 7.6, 5 mMMgCl2,
0.1% bovine serum albumin, 0.5 μM [3H]cGMP or [3H]cAMP (40,000 cpm),
activators and inhibitors. The reaction was initiated by adding 10 μl of the tested
fraction containing approximately 20 μg of protein, and was terminated after
15 min by boiling. To separate the product from the substrate, in the first step the
phosphate was liberated from the monophosphate nucleosides by adding Cro-
tulus atrox snake venom (50 μg) followed by incubation for 30 min at 37 °C.
The product (nucleoside) was then separated from the substrate (cyclic
nucleotide) by addition 250 μl of a 1:3 slurry of AG1-X2 Bio-Rad resin in
H2O. The radioactivity of the unbound fraction containing the product was
measured in a Wallac-LKB liquid scintillation counter.
2.6. Analysis of PDE isoenzyme activity
To determine the activity in a sample due to a specific PDE isoform, various
inhibitors or activators were included in the assay [20,22,37]. TheAccession no. Product size (bp) TA (°C)
X62085 556 48
NM030871 375 57
NM022710 382 57
NM031078 485 55
NM031079 442 55
NM017337 265 55
NM017229 427 55
NM013101 233 58
AF202733 787 57
XM214325 539 57
′ NM017032 262 55.3
NM133584 250 57
NM138543 275 55
NM022236 322 57
NM080893 374 57
M74535 322 54.7
AB096020 379 51
NM012769 416 51
NM006258 394 55
NM013012 676 63
NM012675.1 707 57
Fig. 1. Accumulation of cGMP and cAMP in rat peritoneal macrophages
depends on the presence of PDE inhibitors. PEMs were stimulated for 30 min
with an activator of particulate guanylyl cyclase (10 nM ANP) or adenylyl
cyclases (5 μM forskolin) either in the absence or in the presence of PDE
inhibitors, used as follows: 0.5 mM IBMX , 0.1 mM milrinone , or 0.1 mM
dipirydamole. Intracellular cyclic nucleotides (cGMP or cAMP) were then
determined as described in Materials and methods. Data are expressed as mean±
SE of three independent experiments. *P<0.05; **P<0.01 versus trials without
inhibitors.
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chosen to be sufficient for inhibition of the desired PDE, while minimally
inhibiting other PDEs. The calmodulin-stimulated PDE1 activity was defined as
a difference between an activity measured in the presence 1 mM EGTA and that
measured in the presence of 250 μM CaCl2 and 2.4 μM calmodulin [20,37].
Hydrolytic activity of PDE2 against cGMP was defined as that inhibited by
10 μM EHNA [38]. PDE2 activity with cAMP as a substrate was defined as the
increase in PDE activity caused by 1 μM cGMP and was determined in the
presence of 10 μM rolipram and 5 μM milrinone added to block hydrolytic
activities of PDE3 and PDE4, respectively [37]. PDE3 activity was calculated as
that inhibited by 5 μM milrinone [39], whereas PDE5 activity as that inhibited
by 50 nM sildenafil [40]. PDE4 activity was calculated as that inhibited by
10 μM rolipram [16]. Activity of PDE10 and PDE11, with cGMP as a substrate,
was defined as that inhibited by 35 μM zaprinast in the presence of EGTA,
sildenafil, milrinone, and EHNA. PDE10 and PDE11 activity against cAMP was
defined as that inhibited by zaprinast in the presence of EGTA, rolipram and
milrinone. Total PDE activity against cGMP was defined as that measured in the
presence of Ca2+/calmodulin and without PDE inhibitors. The total effective
PDE activity with cAMP as a substrate was determined in the presence of Ca2+/
calmodulin either in the presence or in the absence of cGMP.
2.7. Statistical analysis
Data are presented as means±SE of values obtained from at least three
independent experiments. Differences between two groups were determined
using the unpaired Student t test, assuming P<0.05 to be statistically significant.
3. Results
3.1. Activity of cGMP-hydrolyzing and cGMP-dependent PDEs
in rat peritoneal macrophages
Synthesis of cGMP or cAMP in isolated rat PEMs was
stimulated by atrial natriuretic factor (ANP) or by forskolin,
respectively. Accumulation of cGMP and cAMP was then
measured in cells untreated or treated with the PDE inhibitor
IBMX, the non-selective inhibitor of most cGMP-hydrolyzing
PDEs dipirydamole, and the PDE3 inhibitor milrinone. In
accordance with their specificities, ANP stimulated synthesis of
cGMP but not cAMP, while forskolin exerted the opposite effect
(Fig. 1). The effect of PDE inhibitors on cGMP accumulation is
shown in the upper panel of Fig. 1. In their absence, cGMP
accumulated to the level of 210±21 fmol/106 cells and
increased almost two-fold (380±80 fmol/106 cells) in the
cells treated with ANP. Accumulation of cGMP in control
PEMs was significantly higher in the presence of IBMX (470±
70 fmol/106 cells) and dipirydamole (330±44 fmol/106 cells).
Cells treated with ANP in the presence of these inhibitors
accumulated about four-fold more cGMP than controls. At the
same time the presence of milrinone did not affect cGMP levels
in control PEMs. After stimulation of PEMs with ANP in the
presence of milrinone, cGMP reached a value of 670±53 fmol/
106 cells, which was less than 50% of the values measured in
the presence of IBMX or dipirydamole. The level of cAMP
measured in the absence of PDE inhibitors was equal to 260±
56 fmol/106 cells and increased about three-fold in forskolin-
treated PEMs (Fig. 1, lower panel). The presence of IBMX
resulted in a two-fold elevation of basal cAMP in control cells
(570±84 fmol/106 cells), which further increased almost four-
fold in forskolin-treated PEMs. In control PEMs the presence of
milrinone only slightly affected cAMP level (370±19 fmol/106cells) but it caused significant increase in cAMP in forskolin-
treated cells (1270±140 fmol/106 cells). Taken together, these
results clearly show that cGMP and cAMP are hydrolyzed in
intact PEMs by PDEs exhibiting different sensitivities to used
inhibitors. In order to characterize these PDEs more precisely, in
the next experiments PDE activity was evaluated against cGMP
and against cAMP in soluble and particulate fractions of PEMs
(Fig. 2, Table 2). PDE activity was measured in each fraction
using [3H]cGMP or [3H]cAMP as a substrate and PDE isoforms
involved in hydrolysis were determined using combinations of
selective inhibitors as described in Materials and methods. PDE
activity was measured at 0.5 μM concentration of substrates,
based on the assumption that intracellular concentration of
cGMP and cAMP is usually in the range of 0.1 and 1.0 μM [21]
and in accordance with other similar studies [20,37,41]. To
activate various isoforms of PDEs, cGMP or Ca2+-loaded
calmodulin were applied as their allosteric activators. Analysis
of PDE activity against cGMP revealed the presence of PDE1-3,
PDE5, and presumably PDE10 and/or PDE11 (PDE10/11)
(Fig. 2A). When cAMP was used as a substrate, PDE2, PDE3,
PDE4, and again PDE10/11, contributed to the PDE activity
(Fig. 2B and C). Both cellular fractions contained PDEs, which
were able to hydrolyze cGMP as well as cAMP in a cGMP-
dependent manner. The estimation of their fractional contribu-
tion to the total cGMP-hydrolyzing activity, indicated PDE2 as
the most active PDE in rat PEMs (Table 2). PDE1, PDE3, PDE5,
Table 2
Estimated contribution* of individual PDE isoforms to cGMP-regulated PDE
activity in rat PEM
PDE family Substrate
cGMP cAMP
Cytosolic fraction PDE1 10.7±1.4 ND
PDE2 56.2±1.4 66.9±2.5A
PDE3 9.7±0.2 61.7±6.5B
PDE4 ND 34.0±1.8B
PDE5 1.6±1.02 ND
PDE10 and PDE11 16.3±0.6 2.1±0.1A
4.1±8.7B
Membrane fraction PDE1 ND ND
PDE2 82.7±6.6 17.8±0.1A
PDE3 12.4±5.3 12.8±1.5B
PDE4 ND 81.2±1.1B
PDE5 ND ND
PDE10 and PDE11 2.0±1.4 ND
(*) Expressed as percent of total PDE activity. In the case of cAMP, the total
PDE hydrolyzing activity was determined either in the presence (A) or in the
absence (B) of 1 μM cGMP. (ND), not detected.
Fig. 3. Expression of TNFα in rat peritoneal macrophages. The mRNA of TNFα
was detected using RT-PCR. Lanes contain the cDNA obtained from resident
peritoneal macrophages (RPM), RPM cultured for 3 h in the presence of 1 μg/ml
LPS, freshly isolated peritoneal exudate macrophages (PEM), PEM cultured for
24 h (24 h PEM), 24 h PEM cultured additionally 3 h in the presence of 1 μg/ml
LPS, and 24 h PEM cultured additionally 24 h in the presence of 1 μg/ml LPS.
HPRT was used as a loading control to ensure that similar amounts of cDNA
were used.
Fig. 2. Activity of cGMP-hydrolyzing and cGMP-dependent PDEs in rat
peritoneal macrophages. PEMs were homogenized, resolved to soluble and
particulate fractions, and the PDE activity was determined in each fraction using
either [3H]cGMP (A) or [3H]cAMP (B and C) as a substrate. In the case of
cAMP hydrolysis, the PDE activity was determined either in the absence (B) or
in the presence of 1.0 μM cGMP (C). Activities of the indicated PDEs were
determined using activators or inhibitors, as described in Materials and methods.
The normalized PDE activity is expressed as picomoles of cyclic nucleotide
hydrolyzed per minute in a sample containing 1 mg of total protein. The mean±
SE of values from at least three independent experiments are presented.
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smaller extent. The presence of PDE2, PDE3, and PDE10/11
was confirmed in experiments, which used cAMP as a substrate.
However, in this case PDE2, PDE3, and PDE4 showed high
hydrolytic activity (Table 2, Fig. 2B and C).
3.2. Expression of PDEs in rat peritoneal macrophages
correlates with activation of cells and is up-regulated by LPS
The PDE activity profile showed that rat PEMs possibly
express five different PDE isoforms, which hydrolyze cGMP
and are regulated by this nucleotide. Since freshly isolated
PEMs are highly activated [2,32], it was possible that the
expression of PDEs was also up-regulated in these cells.
Therefore, we used RT-PCR to compare their expression at themRNA level in resident peritoneal macrophages (RPMs),
PEMs, and PEMs kept in culture for 24 h in order to deactivate.
To find out whether these ‘resting’ PEMs could be again
activated, they were treated for 3 or 24 h with LPS. The
expression of TNFα was used as an indicator of macrophage
activation. The results obtained (Fig. 3) showed that mRNA of
TNFα was not present in RPMs and a very low level of its
expression was observed in 24 h cultured PEMs. At the same
time, freshly isolated PEMs and both RPMs and ‘resting’ PEMs
treated with LPS showed high expression of TNFα. The highest
level of mRNA was noted in freshly isolated PEMs. Similar
changes were observed in the expression of PDEs (Fig. 4). In
unstimulated RPMs only mRNA of PDE3B, PDE4B, PDE4D,
and PDE11A was present. After stimulation with LPS, the
expression of PDE3B, PDE4B, and PDE4D increased and the
mRNA of PDE1C, PDE5A, and PDE10A appeared. Freshly
isolated PEMs expressed mRNA of PDE1B, PDE2A, PDE3A,
PDE3B, PDE4A, PDE4B, PDE4D, PDE5A, PDE10A, and
PDE11A (lane 3 in Fig. 4). In 24 h cultured deactivated PEMs
Fig. 4. Effect of incubation and LPS on expression of PDEs in rat peritoneal
macrophages. The mRNA of PDEs was detected using RT-PCR. Lanes 1–7
contain cDNA of RPMs, RPMs cultured for 3 h in the presence of 1 μg/ml LPS,
PEMs, 24 h PEMs, 24 h PEMs cultured additionally 3 h in the presence of
1 μg/ml LPS, 24 h PEMs cultured additionally 24 h in the presence of 1 μg/ml
LPS, and positive controls, respectively. The cDNA from rat heart was used as a
positive control of PDE3A and PDE3B expression, cDNA from rat lung as a
control of PDE4 isoforms, and cDNA from rat brain was used as a control for
other PDEs. HPRTwas used as a loading control to ensure that similar amounts
of cDNA were used.
Fig. 5. Effect of incubation and LPS on expression of GC and PKG in rat
peritoneal macrophages. The mRNA of GCs and PKG was detected using RT-
PCR. Lanes 1–7 contain cDNA of RPMs, RPMs cultured for 3 h in the presence
of 1 μg/ml LPS, PEMs, 24 h PEMs, 24 h PEMs cultured additionally 3 h in the
presence of 1 μg/ml LPS; (6), 24 h PEMs cultured additionally 24 h in the
presence of 1 μg/ml LPS, and positive controls, respectively. HPRTwas used as
a loading control to ensure that similar amounts of cDNA were used.
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completely disappeared, while mRNA of other PDE isoforms
was markedly decreased. Interestingly, only small changes were
observed in mRNA of PDE4A, PDE4B, and PDE4D. Treatment
of ‘resting’ PEMs with LPS recovered the expression of all
other PDEs detected in freshly isolated PEMs (lanes 5 and 6).
None of the examined cells expressed PDE1A or PDE9A.3.3. Activity of PDEs is affected by LPS in rat peritoneal
macrophages
The RT-PCR data demonstrated that expression of most
detected PDEs depended on the activation state of macro-
phages and was up-regulated in freshly isolated PEMs and
LPS-treated cells. To find out whether the expression of other
enzymes involved in cGMP signaling is also affected by the
activation of macrophages, we examined expression of GC and
PKG in RPMs, PEMs, ‘resting’ PEMs, and ‘resting’ PEMs
treated with LPS (Fig. 5). Expression of GC-A remained almost
unchanged in cells treated for 3 h with LPS and even decreased
in PEMs treated with LPS for 24 h. It was higher in PEMs than
in RPMs. None of the examined cells expressed sGC and PKG
I. Thus a correlation existed between expression of TNF-α and
PDEs and not other enzymes of the cGMP pathway. Although
expression of PDEs mRNA was increased with activation of
macrophages, it was not obvious whether a similar relationship
existed at the level of PDE activity. To examine it, the PDE
activity was measured in cellular fractions of freshly isolated
PEMs, ‘resting’ PEMs, and ‘resting’ PEMs treated with LPS.
The results are shown in Fig. 6. As it was observed for mRNA
of most PDEs, the PDE activity was high in freshly isolated
PEMs, decreased in 24 h cultured PEMs, and was again
reconstituted in 24 h PEMs treated with LPS. The changes of
activity accompanying prolonged incubation and caused by
LPS were especially pronounced in the case of PDE2 and
PDE3.
4. Discussion
Activation of mononuclear phagocytes is accompanied by
elevated expression of proinflammatory cytokines TNFα, IL-1,
IL-6, IL-12. To facilitate optimal conditions for their function
Fig. 6. Variability of PDE activity in rat peritoneal macrophages. PDE activities were determined in PEMs, 24 h PEMs, and 24 h PEMs cultured additionally for 3 h in
the presence of 1 μg/ml LPS. Macrophages were homogenized, resolved to soluble and particulate fractions, and the PDE activity was determined in each fraction
using either [3H]cGMP (A) or [3H]cAMP (B) as a substrate. In the case of cAMP hydrolysis, the PDE activity was determined either in the absence or in the presence of
1.0 μM cGMP (cAMP+cGMP). Activities of the individual isoforms were determined using activators or inhibitors, as described in Materials and methods. The
normalized PDE activity is expressed as picomoles of cyclic nucleotide hydrolyzed per minute in a sample containing 1 mg of total protein. The mean±SE of values
from at least three independent experiments are presented. *P<0.05; #P<0.01 versus trials with PEMs.
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of several other proteins is also elevated [3]. For example,
antiinflammatory effects of cAMP can be bypassed by
increased expression of PDEs. And indeed, it has recently
been shown that expression of PDE4B is up-regulated by LPS
in monocytes and macrophages [4,24] and this PDE4 isoform
was demonstrated to be responsible for synthesis of TNFα
induced by LPS [16,42]. Similarly to cAMP, increased cGMP
has also been shown to inhibit release of TNFα and nitric oxide
in cells of myeloid lineage activated with LPS [28–30,43].
Although detailed underlying mechanisms are not known, it
cannot be excluded that at least in some cases they are based on
the activity of cGMP-regulated PDEs and thus affect intracel-
lular levels of cAMP. Inhibition of hydrolysis of cAMP by
PDE3 in the presence of cGMP has been shown to be involved
in the regulation of expression of inflammatory cytokines invarious cells including vascular smooth cells [44], alveolar
epithelial cells [23], peripheral blood mononuclear cells [14],
and macrophages [18]. Therefore, the antiinflammatory action
of cGMP may be in fact mediated by cAMP and effects of
cAMP may depend on the level of cGMP. Since cGMP-
regulated PDEs seem to play a central role in both cases, the
principal aim of our studies was to determine which cGMP-
regulated PDEs are actively expressed in activated macro-
phages. The fact that rat peritoneal exudate macrophages
(PEMs) stimulated to produce of cAMP or cGMP accumulated
significantly more of these nucleotides in the presence of PDE
inhibitors clearly showed activity of cAMP- and cGMP-
hydrolyzing PDEs (Fig. 1). Further experiments established
that in the cytosolic fraction of PEMs the total hydrolytic
activity against cGMP was similar to that against cAMP, while
in the particulate fraction activity against cAMP dominated.
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monocyte-derived macrophages (MDM) differentiated in cul-
ture with M-CSF [37], which display morphological and
functional properties of peritoneal macrophages [45,46].
Using various combinations of activators and inhibitors
selective for given PDE families, we found that PDE1, PDE2,
PDE3, PDE4, PDE5, and PDE10/11 were active in freshly
isolated PEMs. Their presence was confirmed by RT-PCR,
which detected mRNA of PDE1B, PDE2A, PDE3A, PDE3B,
PDE4A, PDE4B, PDE4D, PDE5A, PDE10A, and PDE11A.
Except for PDE4 isoforms, these PDEs may hydrolyze cGMP
and/or be regulated by cGMP. Among them, PDEs belonging to
families PDE2, 10, and 11 hydrolyze cGMP and cAMP and are
stimulated by cGMP, while PDE3 activity against cAMP is
inhibited by cGMP [21,47]. Therefore, these PDEs are potential
sites of “cross-talk” between signaling pathways of cAMP and
cGMP. The observation that hydrolysis of cAMP depended on
the presence of cGMP additionally confirmed their presence
and supported our earlier suggestions that rat PEMs express
PDEs that are stimulated by cGMP [33,34].
Analysis of PDE activity showed that the most active of the
PDEs detected in PEMs were PDE2, PDE3, PDE4 and to a
lesser extent PDE1. We noted significantly lower activity of
PDE1 against cGMP in rat PEMs than was found in human
alveolar macrophages [20]. In human alveolar macrophages
PDE1 was cGMP-specific and contributed to more than 80%
of the total cGMP-hydrolyzing activity, while it was only about
10% of the activity in our experiments. We established that
only the PDE1B isoform contributed to the PDE1 activity. The
fact that rat PEMs did not express PDE1A and PDE1C was in
line with lack of measurable PDE1 activity against cAMP. In
the case of PDE1B the KM is about ten-fold higher for cAMP
(24.3 μM) than for cGMP (2.7 μM) and this PDE1 isoform
preferentially hydrolyses cGMP [48]. No PDE1 isoform was
expressed in rat resident macrophages (RPMs) and only
mRNA of PDE1C was detected in LPS-treated RPMs.
However, PDE1 activity against cAMP was observed in
guinea pig PEMs and human MDM [17,37,49]. Unlike rat
macrophages, in guinea pig PEMs and human alveolar
macrophages the PDE1 activity has also been detected in the
membrane fraction [17,20]. Therefore, expression of PDE1
isoforms appears to be variable and dependent on species and
type of macrophage. Although the exact function of this PDE
in macrophages is unknown, the PDE1B isoform has been
recently shown to be a marker of differentiation of human
monocytes to macrophages [37,50,51] and was proposed to
modulate the effects of cGMP on immune functions of
macrophages, especially those which involve Ca2+ [51].
The role of PDE2 in macrophages remains to be elucidated.
Weak PDE2 activity was earlier observed in monocytes [22],
but not in macrophages [17,49,52]. However, recent observa-
tions confirmed the presence of PDE2 in human macrophages
derived from monocytes treated in culture with M-CSF, as well
as in macrophages obtained from the cells of monocytic line
U937 treated with PMA. In both cases, it was one of the two
most active PDEs [37]. The mRNA of PDE2Awas not detected
in rat RPMs but it was relatively abundant in PEMs. Moreover,in PEMs it was found to be the most efficient cGMP hydro-
lyzing PDE and to be activated by cGMP, which proves its
importance in preventing the accumulation of excess cGMP in
cells or their specialized compartments.
The activity of PDE3 has been previously observed in
peritoneal macrophages, but whether it was a product of one or
two genes remained unknown [12,18,52]. In rat PEMs we
detected mRNA of PDE3A and PDE3B, similar to what was
found in human aortic smooth muscle cells [53]. PDE3A exists
mostly in a cytosolic form, while PDE3B as a membrane-
attached protein [53,54]. The presence of transcripts of both
isoforms supports our observation of subcellular distribution of
PDE3 activity. PDE3 activity was higher against cAMP than
cGMP. This is not surprising since the PDE3 isoforms bind
cGMP with high affinity but hydrolyze it about 10-fold more
slowly than cAMP. Therefore, cGMP is a competitive inhibitor
of cAMP hydrolysis [21,39,47]. During differentiation of
human monocytes to macrophages PDE3 activity was shown
to increase in parallel with a decrease in PDE4 activity [22].
Similar pattern of changes in PDE3 and PDE4 activity showed
U937 monocytic cells upon differentiation to macrophages [19].
Therefore, it is likely that in macrophages, PDE3 is the enzyme
which, at least in part, takes over a function from PDE4.
Similarly to PDE4 [5], inhibition of PDE3 has been shown to
decrease TNFα synthesis induced by LPS in PEMs [12,18].
Although we detected mRNA of PDE4 isoforms and observed
that this PDE was still active in rat PEMs. In immune cells,
increase in cGMP and/or cAMP is usually followed by an
inhibition of inflammatory reactions. Assuming that induction
of cGMP in macrophages decreases PDE3 activity against
cAMP, one can explain these effects as a result of elevated
concentration of cAMP.
We also observed expression of PDE5A in rat macrophages,
but its activity was very low. This cGMP-specific and cGMP-
stimulated enzyme was shown to be present in human alveolar
macrophages [20] and in human monocytes. Monocytes also
express PKG [55] and NO-activated GC (sGC) [37]. The
functions of these enzymes in monocytes are not established,
but cooperation of sGC, PKG, and PDE5 is known to be an
important component of cGMP signaling in various other cell
types. For example, relaxation by NO of smooth muscle cells of
blood vessels is strictly controlled by their activities [56].
Interestingly, during differentiation of monocytes, PDE5
activity decreased and was practically absent in macrophages
[22,37]. As shown in our study, sGC and PKG are absent in rat
PEMs. Disappearing activity of PDE5 may, therefore, accom-
pany the loss of sGC and PKG during the differentiation
process. It is also possible that in elicited rat macrophages PDE2
is the enzyme, which takes over the function of PDE5 expressed
in monocytes.
Although we also detected PDE10 and PDE11 in rat
peritoneal macrophages, it was not possible to determine
activity of each of them separately due to a lack of available
selective inhibitors. Nevertheless, the performed experiments
showed that these PDEs contributed markedly to cGMP
hydrolysis and their activity was about two-fold higher against
cGMP than cAMP. Expression of PDE11A in macrophages was
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expression has previously not been reported.
The most important finding of our studies is the observation
that expression and activity of cGMP-regulated PDEs correlates
with activation of macrophages and is up-regulated by LPS.
Freshly isolated PEMs exhibited highest expression of TNFα
and PDEs in comparison with all other cells studied. When
PEMs were kept for 24 h in culture, their activation decreased as
indicated by lower TNFα expression. In parallel, the expression
of the investigated PDEs decreased. The ‘resting’ cells were
reactivated by treatment with LPS and after 3 h showed
expression of PDE3B, PDE10, and PDE11 at the levels observed
in freshly isolated PEMs. Prolonged action with LPS could
recover of expression of the remaining PDEs. At the same time
none or only slight differences were observed in expression of
GC-A. Elevated expression of PDE3, PDE10, and PDE11 after
LPS treatment resulted in their high hydrolytic activity. Increases
in expression of PDE3B caused by LPS suggests that this
isoform may play a role in rat PMs similar to that described for
PDE4B in monocytes [4]. Both of these PDEs are activated at
relatively low concentrations of cAMP (KM=0.3–0.8 μM for
PDE3 and 1.0–3.0 μM for PDE4) [21,58]. By hydrolyzing
cAMP, they may prevent its increase and inhibitory action in
cells activated to an inflammatory response. Thus, elevated
expression of PDEs in activated cells is a putative mechanism
that may counteract the inhibitory effects of cAMP and cGMP
on the synthesis of proinflammatory cytokines. On the other
hand, synthesis of cGMP may cause an increase in the cAMP
concentration through inhibition of its hydrolysis by PDE3.
Based on such a mechanism, the inhibitory effects of cGMP on
TNFα and NO synthesis observed in macrophages could be
explained in terms of known inhibitory effects of cAMP. Such a
PDE3-dependent mechanism has been recently described for
vascular smooth muscle cells where activators of guanylyl
cyclases sGC and GC-C caused inhibition of NF-κB activity
involving PKA but not PKG [44]. Confirmation of whether or
not PDE3 may play similar role in the regulation of NF-κB in
macrophages needs more detailed examination.
In summary, our study demonstrates that freshly isolated
PEMs contain mRNA of PDE1, PDE2, PDE3, PDE4, PDE5,
PDE10, and PDE11. Based on substrate specificity, sensitivity
to inhibitors, and subcellular localization of the hydrolytic
activity, PDE2 and PDE3 were found to be the main cGMP-
regulated PDEs contributing to cyclic nucleotide degradation in
rat PEMs. Expression and activity of individual cGMP-
regulated PDE isoforms varied with the activation state of
macrophages. Except for PDE1 and PDE5, all other cGMP-
regulated PDE isoforms detected in PEMs also hydrolyze
cAMP indicating that cAMP-dependent signaling can be tuned
by cGMP. Further studies are needed to determine which
specific cAMP pathways are sensitive to cGMP and to what
extent cGMP effect depends on the degree of cell activation.
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